Vyne Therapeutics Inc - Asset Resilience Ratio
Vyne Therapeutics Inc (VYNE) has an Asset Resilience Ratio of 16.52% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Vyne Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Vyne Therapeutics Inc's Asset Resilience Ratio has changed over time. See VYNE net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vyne Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vyne Therapeutics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.98 Million | 16.52% |
| Total Liquid Assets | $4.98 Million | 16.52% |
Asset Resilience Insights
- Good Liquidity Position: Vyne Therapeutics Inc maintains a healthy 16.52% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Vyne Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Vyne Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Vyne Therapeutics Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Vyne Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.52% | $4.98 Million | $30.16 Million | -45.65pp |
| 2024-12-31 | 62.16% | $41.59 Million | $66.91 Million | -1.95pp |
| 2023-12-31 | 64.12% | $62.63 Million | $97.69 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $40.76 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $67.05 Million | -- |
| 2020-12-31 | 1.10% | $1.03 Million | $93.74 Million | -57.22pp |
| 2019-12-31 | 58.31% | $46.17 Million | $79.17 Million | -3.67pp |
| 2018-12-31 | 61.99% | $86.74 Million | $139.93 Million | -11.73pp |
| 2017-12-31 | 73.72% | $49.30 Million | $66.87 Million | +9.80pp |
| 2016-12-31 | 63.92% | $26.88 Million | $42.05 Million | -- |
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pa… Read more